期刊文献+

Trp1707Ser突变对重组凝血因子Ⅷ轻链与血管性血友病因子结合作用的影响机制 被引量:1

Study on the impact of Trp1707Ser mutation on the binding mechanism of rF Ⅷ light chain with VWF
原文传递
导出
摘要 目的 探索Trp1707Ser突变对重组凝血因子Ⅷ轻链(rFⅧLC)与血管性血友病因子(VWF)结合作用的影响机制.方法 以长链PCR法构建野生型和Trp1707Ser突变型rFⅧLC原核表达质粒,应用BL21原核表达系统进行蛋白表达,梯度复性法对表达蛋白进行结构复性,SDS-PAGE和Western blot对所得蛋白进行鉴定.复性后蛋白使用GST柱纯化并收集,表面等离子共振法(SPR)检测B区缺失重组FⅧ(BDD-rFⅧ)、野生型和突变型rFⅧLC与VWF的结合活性,结果 SDS-PAGE电泳和Western blot结果显示所表达蛋白(相对分子质量110×10^3)与目的蛋白相符,蛋白纯化峰图显示野生型蛋白表达量高于突变型,SPR检测结果显示BDD-rFⅧ、野生型rFⅧLC、突变型rFVⅧLC蛋白与VWF的结合活性均呈浓度依赖性增强,BDD-rFⅧ与VWF结合KD值(12.2)明显低于野生型rFⅧLC(48.9)和突变型rFⅧLC(46.3),结论 Trp1707Ser突变对原核表达rFⅧLC与VWF的结合作用无明显影响,重链对FⅧ与VWF结合作用的影响更为重要。 Objective To disclose the impact of Trp1707Ser mutation on the binding mechanism ofrFⅧ light chain (rFⅧ LC) with VWF.Methods Using long-chain PCR technique,we constructed rF Ⅷ LC plasmids of both wild type and Trp 1707Ser mutant type.BL21 competent cells were used for protein expression.Gradient renaturation was employed to refold protein.SDS-PAGE and Western blot were performed to identify the molecular weight of expressed protein.GST-Sefinose was used for protein purification and surface plasmon resonance (SPR) was employed to detect binding of B-domain-deleted rF Ⅷ (BDD-rFⅧ),wild and mutant rFⅧ LC with VWF,respectively.Results The results of SDS-PAGE and Western blot showed a molecular weight of 110× 10^3 of expressed proteins,which were consistent with objective proteins.The expression quantity of wild type was higher than that of mutant type.A concentration-dependent combination of the 3 testing proteins with VWF was found.The KD value of BDDrFⅧ (12.2) was lower than that of both rFⅧ LCs (wild type 48.9 and mutant type 46.3),whereas there was no discrepancy between wild rFⅧ LC and mutant rFⅧ LC.Conclusions Trp1707Ser mutation didn't impact the binding of rFⅧ LC expressed by BL21 competent cells with VWF.The heavy chain played a more important role in impacting the binding of FⅧ with VWF.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第11期995-999,共5页 Chinese Journal of Hematology
基金 国家自然科学基金(81170480) 国家自然科学青年基金(81000206)
关键词 血友病A 因子Ⅷ 突变 von WILLEBRAND因子 Hemophilia A Factor Ⅷ Mutation von Willebrand Factor
  • 相关文献

参考文献14

  • 1血友病诊断与治疗中国专家共识(2013年版)[J].中华血液学杂志,2013,34(5):461-463. 被引量:118
  • 2Key NS. Inhibitors in congenital coagulation disorders [J]. Br J Haematol, 2004, 127 (4): 379-391.
  • 3吴希,陆晔玲,丁秋兰,戴菁,奚晓东,王鸿利,王学锋.凝血因子ⅧTrp1707Ser突变患者相关抑制物的结合作用机制研究[J].中华血液学杂志,2013,34(8):691-695. 被引量:2
  • 4Goudemand J. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor Ⅷ concentrates [J]. Haemophilia, 2007, Suppl 5:47-51.
  • 5Oldenburg J, E1-Maarri O, Schwaab R. Inhibitor development in correlation to factor Ⅷ genotypes [J]. Haemophilia, 2002, Suppl 2:23-29.
  • 6Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development [J]. Semin Thromb Hemost, 2003, 29( 1 ): 23-30.
  • 7Thompson AR, Murphy ME, Liu M, et al. Loss of tolerance to exogenous and endogenous factor [J] in a mild hemophilia A patient with an Arg593 to Cys mutation [J]. Blood, 1997, 90 (5): 1902-1910.
  • 8Jacquemin M, Benhida A, Peerlinck K, et al. A human antibody directed to the factor Ⅷ C1 domain inhibits factor Ⅷ cofactor activity and binding to yon Willebrand factor [J]. Blood, 2000, 95( 1 ):156-163.
  • 9Wang XF, Zhao YQ, Yang RC, et al. The prevalence of factor Ⅷ inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A [ J ]. Haemophilia, 2010, 16 (4):632-639.
  • 10Saenko EL, Scandella D. The acidic region of the factor Ⅷ light chain and the C2 domain together form the high affinity binding site for von willebrand factor [ J ]. J Biol Chem, 1997, 272 (29): 18007-18014.

二级参考文献19

  • 1Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor devel.opment in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.J Thromb Haemost, 2010, 8: 1256-1265.
  • 2Borhany M, Kumari M, Shamsi T, et al. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.J Coli Physicians Surg Pak, 2012, 22: 289-293.
  • 3Ananyeva NM, Lee TK,Jain N, et al. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents. Semin Thromb Hemost, 2009, 35: 735-751.
  • 4中华医学会血液学分会血栓与止血学组,中国血友病协作组.血友病诊断与治疗中国专家共识(2013年版).中华血液学杂志,2013,34:461-463.
  • 5Lacroix DS, Wootla B, Dasgupta S, et al. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII.JImmunol, 2006,177: 1355-1363.
  • 6Gouw SC, Gouw HM, Berg VD. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost, 2009, 35: 723-734.
  • 7Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate- severity haemophilia A. Thromb Haemost, 1998,79: 762-766.
  • 8OldenburgJ, Maarri OE, Schwaab R. Inhibitor development in correlation to factor vm genotypes. Haemophilia, 2002, 8: 23-29.
  • 9Peerlinck K,Jacquemin M. Characteristics of inhibitors in mild/ moderate haemophilia A. Haemophilia, 2006, 12:43-47.
  • 10d'Oiron R, Pipe SW,Jacquemin M. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia, 2008,14:138-146.

共引文献118

同被引文献13

  • 1Key NS. Inhibitors in congenital coagulation disorders. British J Haematol, 2004,127:379-391.
  • 2Kreuz W. The role of VWF for the success of immune tolerance in- duction. Thromb Res, 2008,122( Suppl 2) :$7-s12.
  • 3Tkachenko N, Wojas K, Tabarkiewicz J, et al. Generation of dendritic cells from human peripheral blood monocytes-comparison of different culture media. Folia Histochem Cytobiol ,2005,43( 1 ):25-30.
  • 4Schuler G, Romani N. Generation of mature dendritic cells iYom human blood. An improved method with special regard to clinical applicability. Adv Exp Med Biol, 1997,417(1 ):7-13.
  • 5Dasgupta S, Repesse , Bayry J, et al. WF protects F'V from endocytosis by dendritic cells and subsequent presentation to im- mune effectors. Blood, 2007,109(7) :610-612.
  • 6Oldenburg J, E1-Maarri O, Schwaab R. Inhibitor development in cor- relation to factor V genotypes. Haemephil, 2002,8(1 ) :23-29.
  • 7Redlng MT. Immunological aspects of inhibitor development. Hae- mophil, 2006,12 (Suppl 6) :30-35; discussion 35-36.
  • 8Astermark J, Lacroix-Desmazes S, Reding MT. Inhibitor develop- meut. Haemophit, 2008,14( Suppl 3) :36-42.
  • 9Kamate C, Lenting PJ, van den Berg HM, et al. Depletion of CD4 +/Cl)25high regulatory T cells may enhance or uncover factor "V- specific T-cell responses in healthy individuals. J Thromb Haem- ost, 2007,5(7) :611-613.
  • 10Sakaguchl S, Yamaguchi T, Nomura T, ct al. Regulatory T cells and immune tolerance. Cell, 2008,133(8) :775-787.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部